Search Results

Artelo Biosciences, Inc. today announced that it will be participating in the 2024 Pharma Partnering Summit being held May 14th – 15th in San Diego, California.

Cogent Biosciences, Inc. announced it has reached alignment with the U.S. Food and Drug Administration on the Company’s novel patient reported outcome measure, Mastocytosis Symptom Severity Daily Diary, for use in Part 2 of the registration-directed SUMMIT trial evaluating bezuclastinib in Nonadvanced Systemic Mastocytosis patients.

Cogent Biosciences, Inc. announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis.

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell lung cancer, but experts stress the need for diverse and overall survival data.